Abstract
Lafora’s disease (LD) is an autosomal recessive and fatal form of progressive myoclonus epilepsy with onset in late childhood or adolescence. LD is characterised by the presence of intracellular polyglucosan inclusions, called Lafora bodies, in tissues including the brain, liver and skin. Patients have progressive neurologic deterioration, leading to death within 10 years of onset. No preventive or curative treatment is available for LD. At least three genes underlie LD, of which two have been isolated and mutations characterised: EPM2A and NHLRC1. The EPM2A gene product laforin is a protein phosphatase while the NHLRC1 gene product malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Analyses of the structure and function of these gene products suggest defects in post-translational modification of proteins as the common mechanism that leads to the formation of Lafora inclusion bodies, neurodegeneration and the epileptic phenotype of LD. In this review, we summarise the available information on the genetic basis of LD, and correlate these advances with the rapidly expanding information about the mechanisms of LD gained from studies on both cell biological and animal models. Finally, we also discuss a possible mechanism to explain the locus heterogeneity observed in LD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Annesi G, Sofia V, Gambardella A, Candiano IC, Spadafora P, Annesi F, Cutuli N, De Marco EV, Civitelli D, Carrideo S, Tarantino P, Barone R, Zappia M, Quattrone A (2004) A novel exon 1 mutation in a patient with atypical Lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit. Epilepsia 45:294–295
Ben-Neriah Y (2002) Regulatory functions of ubiquitination in the immune system. Nat Immunol 3:20–26
Busard HLSM, Renier WO, Gabreels FJM, Jasper HHJ, Slooff JL, Janssen AJM, van Haelst UJG (1987) Lafora disease: a quantitative morphological and biochemical study of the cerebral cortex. Clin Neuropathol 6:1–6
Cavanagh JB (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res Rev 29:265–295
Chan EM, Bulman DE, Paterson AD, Turnbull J, Andermann E, Andermann F, Rouleau GA, Delgado-Escueta AV, Scherer SW, Minassian BA (2003a) Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 40:671–675
Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW (2003b) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 35:125–127
Chan EM, Omer S, Ahmed M, Bridges LR, Bennett C, Scherer SW, Minassian BA (2004a) Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology 63:565–567
Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P, Scherer SW, Minassian BA (2004b) Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum Mol Genet 13:1117–1129
Delgado-Escueta AV, Ganesh S, Yamakawa K (2001) Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 106:129–138
Fernandez-Sanchez ME, Criado-Garcia O, Heath KE, Garcia-Fojeda B, Medrano-Fernandez I, Gomez-Garre P, Sanz P, Serratosa JM, Rodriguez de Cordoba S (2003) Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation. Hum Mol Genet 12:3161–3171
Ganesh S, Agarwala KL, Ueda K, Akagi T, Shoda K, Usui T, Hashikawa T, Osada H, Delgado-Escueta AV, Yamakawa K (2000) Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual specificity phosphatase associated with polyribosomes. Hum Mol Genet 9:2251–2261
Ganesh S, Shoda K, Amano K, Uchiyama A, Kumuda S, Moriyama N, Hirose S, Yamakawa K (2001a) Mutation screening for Japanese Lafora’s disease patients: identification of novel sequence variants in the coding and upstream regulatory regions of the EPM2A gene. Mol Cell Probes 15:281–289
Ganesh S, Agarwala KL, Amano K, Suzuki T, Delgado-Escueta AV, Yamakawa K (2001b) Regional and developmental expression of Epm2a gene and its evolutionary conservation. Biochem Biophys Res Commun 283:1046–1053
Ganesh S, Delgado-Escueta AV, Suzuki T, Francheschetti S, Riggio C, Avanzini G, Rabinowicz A, Bohlega S, Bailey J, Alonso ME, Rasmussen A, Ochoa A, Prado AJ, Medina MT, Yamakawa K (2002a) Genotype–phenotype correlations for EPM2A mutations in Lafora’s progressive myoclonus epilepsy: exon 1 mutations associate with an early onset cognitive deficit subphenotype. Hum Mol Genet 11:1263–1271
Ganesh S, Suzuki T, Yamakawa K (2002b) Alternative splicing modulates subcellular localization of laforin. Biochem Biophys Res Commun 1291:1134–1137
Ganesh S, Delgado-Escueta AV, Avila MR, Sakamoto T, Machado-Salas J, Hoshii Y, Akagi T, Suzuki T, Amano K, Agarwala KL, Hasegawa Y, Ishihara T, Hashikawa T, Itohara S, Cornford EM, Niki H, Yamakawa K (2002c) Targeted disruption of Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet 11:1251–1262
Ganesh S, Tsurutani N, Suzuki T, Ueda K, Agarwala KL, Osada H, Delgado-Escueta AV, Yamakawa K (2003) The Lafora disease gene product laforin interacts with HIRIP5, a phylogenetically conserved protein containing a NifU-like domain. Hum Mol Genet 12:2359–2368
Ganesh S, Tsurutani N, Suzuki T, Hoshii Y, Ishihara T, Deldago-Escueta AV, Yamakawa K (2004) The carbohydrate-binding domain of Lafora disease protein targets Lafora polyglucosan bodies. Biochem Biophys Res Commun 31:1101–1109
Ganesh S, Tsurutani N, Amano K, Mittal S, Uchikawa C, Delgado-Escueta AV, Yamakawa K (2005) Transcriptional profiling of a mouse model for Lafora disease reveals dysregulation of genes involved in the expression and modification of proteins. Neurosci Lett 387:62–67
Gentry MS, Worby CA, Dixon JE (2005) Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc Natl Acad Sci USA 102:8501–8506
Gomez-Abad C, Gomez-Garre P, Gutierrez-Delicado E, Saygi S, Michelucci R, Tassinari CA, Rodriguez de Cordoba S, Serratosa JM (2005) Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 64:982–986
Gomez-Garre P, Sanz Y, Rodriguez De Cordoba SR, Serratosa JM (2000) Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. Eur J Hum Genet 8:946–954
Ianzano L, Zhao XC, Minassian BA, Scherer SW (2003) Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product. Genomics 81:579–587
Ianzano L, Young EJ, Zhao XC, Chan EM, Rodriguez MT, Torrado MV, Scherer SW, Minassian BA (2004) Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A) causes Lafora progressive myoclonus epilepsy. Hum Mutat 23:170–176
Ki CS, Kong SY, Seo DW, Hong SB, Kim HJ, Kim JW (2003)Two novel mutations in the EPM2A gene in a Korean patient with Lafora’s progressive myoclonus epilepsy. J Hum Genet 48:51–54
Lohi H, Ianzano L, Zhao XC, Chan EM, Turnbull J, Scherer SW, Ackerley CA, Minassian BA (2005a) Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum Mol Genet 14:2727–2736
Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, Turnbull J, Zhao XC, Ianzano L, Paterson AD, Sutter NB, Ostrander EA, Andre C, Shelton GD, Ackerley CA, Scherer SW, Minassian BA (2005b) Expanded repeat in canine epilepsy. Science 307:81
Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CY, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead OC III, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20:171–174
Minassian BA, Ianzano L, Meloche M, Andermann E, Rouleau GA, Delgado-Escueta AV, Scherer SW (2000a) Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology 55:331–333
Minassian BA, Ianzano L, Delgado-Escueta AV, Scherer SW (2000b) Identification of new and common mutations in the EPM2A gene in Lafora disease. Neurology 54:488–490
Robitaille Y, Carpenter S, Karpati G, DiMauro SD (1980) A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora’s disease and normal ageing. Brain 103:315–336
Sainz J, Minassian BA, Serratosa JM, Gee MN, Sakamoto LM, Iranmanesh R, Bohlega S, Baumann RJ, Ryan S, Sparkes RS, Delgado-Escueta AV (1997) Lafora progressive myoclonus epilepsy: narrowing the chromosome 6q24 locus by recombinations and homozygosities. Am J Hum Genet 61:1205–1205
Sakai M, Austin J, Witmer F, Trueb L (1970) Studies in myoclonus epilepsy (Lafora body form) II polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology 20:160–176
Schwartz GA, Yanoff (1965) Lafora bodies, corpora-amylacea, and Lewy bodies: morphological and histochemical study. Arch Neurobiol 28:800–818
Serratosa JM, Delgado-Escueta AV, Posada I, Shih S, Drury I, Berciano J, Zabala JA, Antunez MC, Sparkes RS (1995) The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet 4:1657–1663
Serratosa JM, Gomez-Garre P, Gallardo ME, Anta B, de Bernabe DB, Lindhout D, Augustijn PB, Tassinari CA, Malafosse RM, Topcu M, Grid D, Dravet C, Berkovic SF, de Cordoba SR (1999) A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 8:345–352
Singh S, Suzuki T, Uchiyama A, Kumada S, Moriyama N, Hirose S, Takahashi Y, Inoue Y, Kimura K, Sawaishi S, Yamakawa K, Ganesh S (2005) Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population. J Hum Genet 50:347–352
Van Heycop Ten Ham MW (1975) Lafora disease, a form of progressive myoclonus epilepsy. In: Vinken PJ, Bruyn GW (eds) The epilepsies. Handbook of clinical neurology 15. North-Holland, Amsterdam, pp 382–422
Wang J, Stuckey JA, Wishart MJ, Dixon JE (2002) A unique carbohydrate binding domain targets the Lafora disease phosphatase to glycogen. J Biol Chem 277:2377–2380
Yokoi S, Nakayama H, Negishi T (1975) Biochemical studies on tissues from a patient with Lafora disease. Clin Chim Acta 62:415–423
Acknowledgements
Financial support from the Department of Science and Technology (New Delhi) and the Council of Scientific and Industrial Research (New Delhi) is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganesh, S., Puri, R., Singh, S. et al. Recent advances in the molecular basis of Lafora’s progressive myoclonus epilepsy. J Hum Genet 51, 1–8 (2006). https://doi.org/10.1007/s10038-005-0321-1
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-005-0321-1
Keywords
This article is cited by
-
Lafora disease: from genotype to phenotype
Journal of Genetics (2018)
-
Loss of malin, but not laforin, results in compromised autophagic flux and proteasomal dysfunction in cells exposed to heat shock
Cell Stress and Chaperones (2017)
-
Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy
Journal of Molecular Medicine (2016)
-
Interdependence of laforin and malin proteins for their stability and functions could underlie the molecular basis of locus heterogeneity in Lafora disease
Journal of Biosciences (2015)
-
Expression, purification and characterization of soluble red rooster laforin as a fusion protein in Escherichia coli
BMC Biochemistry (2014)
